Table 4 Progression-free survival and overall survival of cisplatin/carboplatin, pemetrexed with or without bevacizumab in patients with nonsquamous non-small cell lung cancer
Study | Phase | Induction therapy | Maintenance therapy | PFS (months) | OS (months) |
|---|---|---|---|---|---|
Scagliotti, et al. [5] | 3 | CDDP + PEM | – | 5.3 | 11.8 |
PARAMOUNT [6] | 3 | CDDP + PEM | PEM | 6.9 | – |
AVAPEARL [7] | 3 | CDDP + PEM + BEV | PEM + BEV | 10.2 | NR |
PointBreak [23] | 3 | CBDCA + PEM + BEV | PEM + BEV | 8.6 | 17.7 |
PRONOUNCE [12] | 3 | CBDCA + PEM | PEM | 4.44 | 10.5 |
MAP (The current study) | 2 | CDDP + PEM + BEV | PEM + BEV | 10.8 | 48.0 |